Unani treatment for heavy menstrual bleeding

Comparative clinical study on Dawa-i-khas and Qurs-i-Gulnar in heavy menstrual bleeding

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/02/040084

Enrollment

Registered

2022-02-07

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N924- Excessive bleeding in the premenopausal period

Interventions

Intervention1: Dawa-i-khas: 3gm twice daily for 7 days Control Intervention1: qurs-i-gulnar: 2 tablets thrice daily for 7 days

Eligibility

Inclusion criteria

Inclusion criteria: 1. MBL >80 ml with estimated PBAC score >100. 2. Age group of 18-40 years.

Exclusion criteria

Exclusion criteria: Women with- 1. Known cases of systemic diseases like thyroid dysfunction, diabetes mellitus, hypertension and malignancies. 2. Severe anemia and known cases of bleeding disorders. • History of hormonal contraceptives in last 3 months. • Known cases of Endometriosis, uterine polyps , fibroid >3cm and >3 in number.

Design outcomes

Primary

Measure	Time frame
Changes in PBAC scoreTimepoint: baseline, monthly for 3 months	—

Secondary

Measure	Time frame
Changes in MAUS score, USG pelvis, Hb%.Timepoint: baseline, monthly for 3 months and post trail	—

Countries

India

Contacts

Public ContactDr Kouser FAthima Firdose

National Institite of Unani Medicine

kouser2fathima@gmail.com9141762284

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026